Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141905

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accident and Emergency Departments: Greater Manchester
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what were the average annual waiting times for each accident and emergency department in Greater Manchester in each of the last five years.
tabling member printed	Lord Bradley
uin	HL17449
answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>Data is not available in the format requested.</p> answering member printed Baroness Blackwood of North Oxford question first answered 07/08/2019 11:37:37 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	452 label Biography information for Lord Bradley

1141914

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records: Data Protection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in respect of its guidance Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation, published on 15 July, what is meant by "fair terms" for (1) NHS organisations, and (2) the NHS as a whole.
tabling member printed	Lord Freyberg
uin	HL17458
answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>As set out in the recently published guidance <em>Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation,</em> the Centre of Expertise will offer support to those National Health Service organisations seeking to understand whether proposed data arrangements meet the requirements set out in the five guiding principles. The Centre of Expertise will sit in NHSX. The requirement that terms are agreed which are fair to both an NHS organisation and the wider NHS, is included to ensure, for example, that local NHS trusts consider arrangements which can provide benefits to the whole NHS, not just to an individual trust. This may include a NHS trust providing access to anonymised healthcare data for development of a healthcare product in return for access at a reduced cost to that product for the whole NHS, not just that particular trust. Fair terms should ensure that benefits returned to NHS organisations and the NHS as a whole are commensurate with the outputs that are generated by the data partner. The principles are intended to apply to all NHS organisations at the primary, secondary and tertiary care levels, including national NHS organisations. However, we will consider the inclusion of arm’s length bodies as part of the next phase of work in developing a full policy framework.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17459 HL17460 question first answered 07/08/2019 11:38:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2593 label Biography information for Lord Freyberg

1141915

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records: Data Protection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in respect of its guidance Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation, which organisation or body will hold to account the boards of NHS organisations in ensuring that "any arrangements entered into by their organisation are fair, including recognising and safeguarding the value of the data that is shared and the resources which are generated as a result of the arrangement”.
tabling member printed	Lord Freyberg
uin	HL17459
answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>As set out in the recently published guidance <em>Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation,</em> the Centre of Expertise will offer support to those National Health Service organisations seeking to understand whether proposed data arrangements meet the requirements set out in the five guiding principles. The Centre of Expertise will sit in NHSX. The requirement that terms are agreed which are fair to both an NHS organisation and the wider NHS, is included to ensure, for example, that local NHS trusts consider arrangements which can provide benefits to the whole NHS, not just to an individual trust. This may include a NHS trust providing access to anonymised healthcare data for development of a healthcare product in return for access at a reduced cost to that product for the whole NHS, not just that particular trust. Fair terms should ensure that benefits returned to NHS organisations and the NHS as a whole are commensurate with the outputs that are generated by the data partner. The principles are intended to apply to all NHS organisations at the primary, secondary and tertiary care levels, including national NHS organisations. However, we will consider the inclusion of arm’s length bodies as part of the next phase of work in developing a full policy framework.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17458 HL17460 question first answered 07/08/2019 11:38:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2593 label Biography information for Lord Freyberg

1141916

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records: Data Protection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in respect of its guidance Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation, whether, in referring to NHS organisations, national NHS organisations, pertinent departments and arms-length bodies are required not to enter into “exclusive arrangements for raw data held by them”.
tabling member printed	Lord Freyberg
uin	HL17460
answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>As set out in the recently published guidance <em>Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation,</em> the Centre of Expertise will offer support to those National Health Service organisations seeking to understand whether proposed data arrangements meet the requirements set out in the five guiding principles. The Centre of Expertise will sit in NHSX. The requirement that terms are agreed which are fair to both an NHS organisation and the wider NHS, is included to ensure, for example, that local NHS trusts consider arrangements which can provide benefits to the whole NHS, not just to an individual trust. This may include a NHS trust providing access to anonymised healthcare data for development of a healthcare product in return for access at a reduced cost to that product for the whole NHS, not just that particular trust. Fair terms should ensure that benefits returned to NHS organisations and the NHS as a whole are commensurate with the outputs that are generated by the data partner. The principles are intended to apply to all NHS organisations at the primary, secondary and tertiary care levels, including national NHS organisations. However, we will consider the inclusion of arm’s length bodies as part of the next phase of work in developing a full policy framework.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17458 HL17459 question first answered 07/08/2019 11:38:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2593 label Biography information for Lord Freyberg

1141919

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bacterial Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 9 July (HL16592), what is their view of the proportion of each of the resulting illness, deaths and costs that could be prevented by new efforts to prevent transmission; and what are the costs of new measures introduced in 2019 to prevent transmission of carbapenem-resistant Enterobacteriaceae.
tabling member printed	Baroness Gardner of Parkes
uin	HL17463
answer	answer is ministerial correction date of answer 06/08/2019 answer text <p>Public Health England (PHE) has prioritised collecting the necessary data across the National Health Service to enable estimation and monitoring of the proportion of cases, deaths and costs attributable to carbapenemase-resistant Enterobacteriaceae.</p><p>In May 2015 PHE implemented an enhanced surveillance system of all carbapenemase-producing Gram negative bacteria, which was modified in 2019 to maximise efficiency. The health burden of cases, estimated from these data, will be published in the <em>English Surveillance Programme for Antimicrobial Utilisation Report</em> in November 2019.</p><p>The few published reports of outbreaks have estimated costs of at least £1 million, and up to £5 million, all indicating multi-model control measures are required, as outlined in the PHE toolkit for prevention and control of carbapenemase-producing Enterobacteriaceae which is currently being updated.</p><p>Using national surveillance and patient administration data to develop mathematical models, work is ongoing to estimate the reduction in levels of illness and death when specified detection and control measures are applied by 2020. Developed models will enable associated costs incurred to be estimated and the cost-effectiveness of control measures to be established by 2021.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 06/08/2019 15:07:02 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3596 label Biography information for Baroness Gardner of Parkes

1141940

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gambling: Rehabilitation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 17 July (HL16963 and HL16964), what was the budget of Leeds and York Partnership NHS Trust for funding the NHS Northern Gambling Clinic; and what is the projected cost of that clinic in (1) 2020, (2) 2021, and (3) 2022.
tabling member printed	The Lord Bishop of St Albans
uin	HL17484
answer	answer is ministerial correction date of answer 06/08/2019 answer text <p>NHS England and NHS Improvement have allocated £600,000 to Central and North West London NHS Foundation Trust and £370,000 to Leeds and York Partnership NHS Foundation Trust for gambling harm services provision in 2019/20, which includes funding for these clinics.</p><p> </p><p>GambleAware, an independent charity, is providing additional funding for these clinics. Information on this funding is not held centrally.</p><p> </p><p>Future years’ funding is not yet available.</p><p> </p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17485 question first answered 06/08/2019 14:58:10 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1141941

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Problem Gambling Clinic
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 17 July (HL16963 and HL16964), what was the budget of the Central and North West London NHS Foundation Trust for funding the National Problem Gambling Clinic; and what is the projected cost of that clinic in (1) 2020, (2) 2021, and (3) 2022.
tabling member printed	The Lord Bishop of St Albans
uin	HL17485
answer	answer is ministerial correction date of answer 06/08/2019 answer text <p>NHS England and NHS Improvement have allocated £600,000 to Central and North West London NHS Foundation Trust and £370,000 to Leeds and York Partnership NHS Foundation Trust for gambling harm services provision in 2019/20, which includes funding for these clinics.</p><p> </p><p>GambleAware, an independent charity, is providing additional funding for these clinics. Information on this funding is not held centrally.</p><p> </p><p>Future years’ funding is not yet available.</p><p> </p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17484 question first answered 06/08/2019 14:58:10 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1141956

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Illness: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of reports that referrals to child mental health units from primary schools for pupils aged 11 and under have risen by almost 50 per cent in the last three years.
tabling member printed	Lord Watson of Invergowrie
uin	HL17500
answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>No formal assessment has been made as comparable data is not available at a national level.</p><p>Referral data for children and young people’s mental health services is published by NHS Digital in the Mental Health Services Dataset since 2017. This shows that in 2017/18 there were 259,615 new referrals to children and young people’s mental health services for people aged 0-18 and 381,528 new referrals for the same in 2018/19.</p><p>The number of providers supplying data has increased in 2018/19 and so a direct comparison between the two years is not possible.</p> answering member printed Baroness Blackwood of North Oxford question first answered 07/08/2019 11:38:28 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1241 label Biography information for Lord Watson of Invergowrie

1141957

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
tabling member printed	Lord Willis of Knaresborough
uin	HL17501
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141958

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pertuzumab
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
tabling member printed	Lord Willis of Knaresborough
uin	HL17502
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4151 label Biography information for Lord Willis of Knaresborough